Proteome Sciences Interim Earnings Report

Proteome Sciences EPS Results

• Actual EPS: -GBX 0.73
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Proteome Sciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Proteome Sciences Announcement Details

• Quarter: Interim
• Date: 9/25/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Proteome Sciences (LON:PRM) provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.